Name | Number of supported studies | Average coverage | |
---|---|---|---|
epithelial cell | 4 studies | 32% ± 12% | |
macrophage | 4 studies | 19% ± 4% | |
monocyte | 3 studies | 18% ± 2% | |
non-classical monocyte | 3 studies | 20% ± 4% | |
CD16-positive, CD56-dim natural killer cell, human | 3 studies | 16% ± 1% | |
endothelial cell | 3 studies | 22% ± 3% |
Name | Number of supported studies | Average coverage | |
---|---|---|---|
peripheral blood | 3 studies | 20% ± 4% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
lung | 100% | 4272.39 | 578 / 578 | 100% | 69.89 | 1152 / 1155 |
prostate | 100% | 2879.82 | 245 / 245 | 100% | 59.87 | 500 / 502 |
esophagus | 100% | 2742.00 | 1445 / 1445 | 99% | 89.49 | 182 / 183 |
breast | 100% | 2633.72 | 459 / 459 | 99% | 76.57 | 1111 / 1118 |
ovary | 100% | 2126.94 | 180 / 180 | 99% | 69.45 | 427 / 430 |
intestine | 100% | 3439.49 | 966 / 966 | 99% | 56.93 | 523 / 527 |
stomach | 100% | 2245.84 | 359 / 359 | 99% | 62.66 | 283 / 286 |
liver | 100% | 3203.80 | 226 / 226 | 99% | 42.40 | 401 / 406 |
thymus | 100% | 2732.66 | 653 / 653 | 99% | 41.43 | 597 / 605 |
uterus | 100% | 2770.98 | 170 / 170 | 98% | 73.47 | 452 / 459 |
bladder | 100% | 2618.10 | 21 / 21 | 98% | 56.04 | 494 / 504 |
kidney | 100% | 2263.37 | 89 / 89 | 97% | 42.90 | 876 / 901 |
pancreas | 98% | 2312.39 | 323 / 328 | 98% | 54.89 | 174 / 178 |
skin | 100% | 1863.09 | 1803 / 1809 | 92% | 53.93 | 434 / 472 |
adrenal gland | 100% | 2618.62 | 258 / 258 | 69% | 14.26 | 158 / 230 |
brain | 67% | 606.20 | 1765 / 2642 | 83% | 24.84 | 585 / 705 |
adipose | 100% | 3062.97 | 1204 / 1204 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 100% | 61.34 | 29 / 29 |
spleen | 100% | 4523.20 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 104.81 | 45 / 45 |
blood vessel | 99% | 1606.20 | 1326 / 1335 | 0% | 0 | 0 / 0 |
heart | 98% | 1147.46 | 847 / 861 | 0% | 0 | 0 / 0 |
muscle | 97% | 1282.93 | 780 / 803 | 0% | 0 | 0 / 0 |
peripheral blood | 97% | 3940.56 | 902 / 929 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 33% | 7.28 | 26 / 80 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0007219 | Biological process | Notch signaling pathway |
GO_0045087 | Biological process | innate immune response |
GO_0140861 | Biological process | DNA repair-dependent chromatin remodeling |
GO_0006302 | Biological process | double-strand break repair |
GO_0032092 | Biological process | positive regulation of protein binding |
GO_0051607 | Biological process | defense response to virus |
GO_0051865 | Biological process | protein autoubiquitination |
GO_0006511 | Biological process | ubiquitin-dependent protein catabolic process |
GO_1902966 | Biological process | positive regulation of protein localization to early endosome |
GO_2000646 | Biological process | positive regulation of receptor catabolic process |
GO_0070936 | Biological process | protein K48-linked ubiquitination |
GO_0045893 | Biological process | positive regulation of DNA-templated transcription |
GO_0008333 | Biological process | endosome to lysosome transport |
GO_0035563 | Biological process | positive regulation of chromatin binding |
GO_0015031 | Biological process | protein transport |
GO_0051444 | Biological process | negative regulation of ubiquitin-protein transferase activity |
GO_0002230 | Biological process | positive regulation of defense response to virus by host |
GO_1900182 | Biological process | positive regulation of protein localization to nucleus |
GO_0000077 | Biological process | DNA damage checkpoint signaling |
GO_0005769 | Cellular component | early endosome |
GO_0031901 | Cellular component | early endosome membrane |
GO_0005764 | Cellular component | lysosome |
GO_0032991 | Cellular component | protein-containing complex |
GO_0005654 | Cellular component | nucleoplasm |
GO_0005829 | Cellular component | cytosol |
GO_0005737 | Cellular component | cytoplasm |
GO_0005765 | Cellular component | lysosomal membrane |
GO_0005634 | Cellular component | nucleus |
GO_0019899 | Molecular function | enzyme binding |
GO_0004857 | Molecular function | enzyme inhibitor activity |
GO_0042393 | Molecular function | histone binding |
GO_0140852 | Molecular function | histone ubiquitin ligase activity |
GO_0097677 | Molecular function | STAT family protein binding |
GO_0141000 | Molecular function | histone H4K91 ubiquitin ligase activity |
GO_0140768 | Molecular function | protein ADP-ribosyltransferase-substrate adaptor activity |
GO_0046872 | Molecular function | metal ion binding |
GO_0044389 | Molecular function | ubiquitin-like protein ligase binding |
GO_0004842 | Molecular function | ubiquitin-protein transferase activity |
GO_0005515 | Molecular function | protein binding |
Gene name | DTX3L |
Protein name | E3 ubiquitin-protein ligase DTX3L (EC 2.3.2.27) (B-lymphoma- and BAL-associated protein) (Protein deltex-3-like) (RING-type E3 ubiquitin transferase DTX3L) (Rhysin-2) (Rhysin2) |
Synonyms | BBAP |
Description | FUNCTION: E3 ubiquitin-protein ligase which, in association with ADP-ribosyltransferase PARP9, plays a role in DNA damage repair and in interferon-mediated antiviral responses . Monoubiquitinates several histones, including histone H2A, H2B, H3 and H4 . In response to DNA damage, mediates monoubiquitination of 'Lys-91' of histone H4 (H4K91ub1) . The exact role of H4K91ub1 in DNA damage response is still unclear but it may function as a licensing signal for additional histone H4 post-translational modifications such as H4 'Lys-20' methylation (H4K20me) . PARP1-dependent PARP9-DTX3L-mediated ubiquitination promotes the rapid and specific recruitment of 53BP1/TP53BP1, UIMC1/RAP80, and BRCA1 to DNA damage sites . By monoubiquitinating histone H2B H2BC9/H2BJ and thereby promoting chromatin remodeling, positively regulates STAT1-dependent interferon-stimulated gene transcription and thus STAT1-mediated control of viral replication . Independently of its catalytic activity, promotes the sorting of chemokine receptor CXCR4 from early endosome to lysosome following CXCL12 stimulation by reducing E3 ligase ITCH activity and thus ITCH-mediated ubiquitination of endosomal sorting complex required for transport ESCRT-0 components HGS and STAM . In addition, required for the recruitment of HGS and STAM to early endosomes . In association with PARP9, plays a role in antiviral responses by mediating 'Lys-48'-linked ubiquitination of encephalomyocarditis virus (EMCV) and human rhinovirus (HRV) C3 proteases and thus promoting their proteasomal-mediated degradation . . |
Accessions | Q8TDB6 ENST00000296161.9 [Q8TDB6-1] ENST00000383661.3 [Q8TDB6-2] |